Gore & Associates announced new 12-month findings from the global GORE VIABAHN FORTEGRA Venous Stent IVC trial, which evaluat ...
The assessment of the inferior vena cava (IVC) and central venous pressure (CVP) has emerged as a pivotal aspect in the optimisation of haemodynamic management across a range of clinical settings.
Impact of upstaging from cT2a–b to pT3a on overall survival (OS) among patients with renal cell carcinoma. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This ...
The Crux retrievable inferior vena cava filter (VCF) represents the first significant innovation in vena cava filters in 40 years. Crux Biomedical designed the device to overcome problems associated ...
Get Inferior Vena Cava News on Telangana Today, Inferior Vena Cava latest news, Inferior Vena Cava news, | Telangana Today ...
High expression of sialylated cancer-derived IgG and survival in metastatic clear cell renal cell carcinoma. Hypoxia-inducible factor-2 alpha (HIF-2α) target activation and clinical outcomes in 942 ...
W.L. Gore & Associates has received FDA approval for the Gore Viabahn Fortegra Venous Stent — the first device indicated to treat deep venous disease in the inferior vena cava, as well as the iliac ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results